uses pig islets to replace human islets that have been destroyed by type 1 diabetes.

At Diatranz Otsuka Limited, we are developing cellular therapies to improve the lives of people living with serious disease.

DIABECELL is our most advanced product in development. It is being developed to treat type 1 diabetes, a disease affecting the lives of more than 8 million adults and 3 million children worldwide.